Who are BEVA+SOC's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Avastin®, paclitaxel, carboplatin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/beva-soc.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

BEVA+SOC — Competitive Intelligence Brief

BEVA+SOC (BEVA+SOC) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-angiogenic monoclonal antibody + chemotherapy combination. Area: Oncology.

phase 3 Anti-angiogenic monoclonal antibody + chemotherapy combination VEGF (vascular endothelial growth factor) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

BEVA+SOC (BEVA+SOC) — Assistance Publique - Hôpitaux de Paris. BEVA+SOC combines bevacizumab (an anti-VEGF monoclonal antibody) with standard of care chemotherapy to inhibit tumor angiogenesis and improve chemotherapy efficacy.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
BEVA+SOC TARGET	BEVA+SOC	Assistance Publique - Hôpitaux de Paris	phase 3	Anti-angiogenic monoclonal antibody + chemotherapy combination	VEGF (vascular endothelial growth factor)
Avastin®, paclitaxel, carboplatin	Avastin®, paclitaxel, carboplatin	Jiangsu HengRui Medicine Co., Ltd.	phase 3	Anti-angiogenic monoclonal antibody + chemotherapy combination	VEGF (bevacizumab); tubulin (paclitaxel); DNA (carboplatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-angiogenic monoclonal antibody + chemotherapy combination class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BEVA+SOC — Competitive Intelligence Brief. https://druglandscape.com/ci/beva-soc. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab